- Home
- IDYA vs SPNT Comparison
IDYA vs SPNT Comparison
Compare IDYA & SPNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IDYA | SPNT |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.3B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | IDYA | SPNT |
|---|---|---|
| Price | $34.67 | $20.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 3 |
| Target Price | ★ $49.33 | $24.00 |
| AVG Volume (30 Days) | ★ 964.1K | 731.8K |
| Earning Date | 02-12-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.45 |
| Revenue | $214,834,000.00 | ★ $2,859,100,000.00 |
| Revenue This Year | $2,688.43 | $0.89 |
| Revenue Next Year | N/A | $6.87 |
| P/E Ratio | ★ N/A | $13.76 |
| Revenue Growth | ★ 5377.66 | 6.92 |
| 52 Week Low | $13.45 | $13.26 |
| 52 Week High | $39.28 | $22.89 |
Technical Indicators
Market Signals| Indicator | IDYA | SPNT |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 39.21 |
| Support Level | $34.75 | $19.72 |
| Resistance Level | $37.81 | $20.59 |
| Average True Range (ATR) | 1.70 | 0.56 |
| MACD | -0.16 | -0.17 |
| Stochastic Oscillator | 31.09 | 12.73 |
Price Performance
Historical ComparisonAbout IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About SPNT SiriusPoint Ltd.
SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.